Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Conditions
Brief summary
This study is a single-center, retrospective cohort study. The purpose is to evaluate different perioperative treatment options on the efficacy and survival prognosis of locally advanced GC/GEJC, clarify whether the tumor regression grade can influence survival of patients using neoadjuvant therapy. Moreover, we aim to explore the clinical and pathological characteristics that will affect the long-term survival benefit of patients who underwent perioperative treatment.
Interventions
PROCEDUREChemo only
Patients who only used chemotherapy during neodajuvant treatment period
PROCEDUREImmunochemotherapy
Patients who used immunotherapy combined with chemotherapy during neodajuvant treatment period
Sponsors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* (1) Pathologically diagnosed as gastric adenocarcinoma or esophageal-gastric junction adenocarcinoma, and has not received any anti-tumor treatment before (such as surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.) * (2) cT3-4N+M0 (according to AJCC version 8 stage) confirmed as resectable by CT or MRI. * (3) Patients who underwent adjuvant therapy before surgery. * (4) After neoadjuvant therapy , radical resection was performed at the Cancer Hospital of the Chinese Academy of Medical Sciences. * (5) Patients who have complete clinical, pathological and imaging data.
Exclusion criteria
* (1) It is known that peritoneal metastasis or peritoneal irrigation solution cytology is positive (CY1P0) or there is distant metastasis (according to the 8th edition of AJCC). * (2) There are unresectable factors, including irresectable tumor causes or surgical contraindications that are irresectable or refuse surgery. * (3) Those who have suffered from other malignant tumors within 5 years or at the same time, except for cured skin basal cell carcinoma and cervical cancer in situ and breast cancer in situ. * (4) Those who have had radiotherapy, interventional treatment and other local therapists before surgery. * (5) Patients whose key diagnosis and treatment information records were missing.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| OS | From the start date of cycle 1 (each cycle is 14 days or 21 days) neoadjuvant therapy until the date of first documented death from any cause, assessed up to 100 months. | overall survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| EFS | From the start date of cycle 1 (each cycle is 14 days or 21 days) neoadjuvant therapy until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 100 months. | event free survival |
| DFS | From the start date of cycle 1 (each cycle is 14 days or 21 days) adjuvant therapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months. | disease free survival |
Countries
China
Outcome results
None listed